Tumor growth inhibition modeling to support the starting dose for dacomitinib

Dacomitinib is a second‐generation, irreversible EGFR tyrosine kinase inhibitor for first‐line treatment of patients with metastatic non‐small cell lung cancer and EGFR‐activating mutations. A high rate of dose reductions in the pivotal trial led to an observed inverse exposure‐response (ER) relatio...

Descripción completa

Detalles Bibliográficos
Autores principales: Fostvedt, Luke K., Nickens, Dana J., Tan, Weiwei, Parivar, Kourosh
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9893889/
https://www.ncbi.nlm.nih.gov/pubmed/35818811
http://dx.doi.org/10.1002/psp4.12841

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9893889/
https://www.ncbi.nlm.nih.gov/pubmed/35818811
http://dx.doi.org/10.1002/psp4.12841

Ejemplares similares